{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:29:58Z","timestamp":1782509398405,"version":"3.54.5"},"reference-count":294,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA036727"],"award-info":[{"award-number":["P30 CA036727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA127297"],"award-info":[{"award-number":["P50 CA127297"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016764","name":"Fred and Pamela Buffett Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.109882","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T08:04:46Z","timestamp":1677485086000},"page":"109882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Highlights into historical and current immune interventions for cancer"],"prefix":"10.1016","volume":"117","author":[{"given":"Kathryn","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Al-Kadhimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-6056","authenticated-orcid":false,"given":"James E.","family":"Talmadge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.109882_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2023.109882_b0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0015","doi-asserted-by":"crossref","unstructured":"Stanley J. Oiseth , M.S.A. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J. Cancer Metastasis Treatment 3 (2017) 250-261.","DOI":"10.20517\/2394-4722.2017.41"},{"key":"10.1016\/j.intimp.2023.109882_b0020","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/s-0029-1196806","article-title":"Ueber die Z\u00fcchtung der Erysipelkokken auf k\u00fcnstlichem N\u00e4hrboden und ihre \u00dcbertragbarkeit auf den Menschen","volume":"8","author":"Fehleisen","year":"1882","journal-title":"Dtsch. Med. Wochenschr."},{"key":"10.1016\/j.intimp.2023.109882_b0025","first-page":"137","article-title":"Aus der Sitzung der medicinischen Section vom 13","volume":"5","author":"Busch","year":"1868","journal-title":"Berl Klin Wochenschr"},{"key":"10.1016\/j.intimp.2023.109882_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893","author":"Coley","year":"1991","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.intimp.2023.109882_b0035","first-page":"1","article-title":"The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus)","volume":"3","author":"Coley","year":"1910","journal-title":"Proc. R. Soc. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0040","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/214992a0","article-title":"Cellular basis of the immunological defects in thymectomized mice","volume":"214","author":"Miller","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109882_b0045","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.1.5023.841","article-title":"Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications","volume":"1","author":"Burnet","year":"1957","journal-title":"Br. Med. J."},{"key":"10.1016\/j.intimp.2023.109882_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000386035","article-title":"The concept of immunological surveillance","volume":"13","author":"Burnet","year":"1970","journal-title":"Prog. Exp. Tumor Res."},{"key":"10.1016\/j.intimp.2023.109882_b0055","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0060","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1126\/science.183.4124.534","article-title":"Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice","volume":"183","author":"Stutman","year":"1974","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109882_b0065","first-page":"226","article-title":"Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes","volume":"21","author":"Pross","year":"1975","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0070","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","article-title":"Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution","volume":"137","author":"Steinman","year":"1973","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0080","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109882_b0085","first-page":"2617","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"178","author":"van der Bruggen","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0090","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J. Urol."},{"issue":"Suppl 5","key":"10.1016\/j.intimp.2023.109882_b0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109882_b0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1126\/science.362.6410.13","article-title":"Cancer immunotherapy sweeps Nobel for medicine","volume":"362","author":"Kaiser","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109882_b0105","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2023.109882_b0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3\u2013potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000414677","article-title":"Therapeutic potential of cytokines: a comparison of preclinical and clinical studies","volume":"32","author":"Talmadge","year":"1988","journal-title":"Prog. Exp. Tumor Res."},{"key":"10.1016\/j.intimp.2023.109882_b0120","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.intimp.2023.109882_b0125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0130","doi-asserted-by":"crossref","unstructured":"Italian Cooperative Study Group on Chronic Myeloid, L. et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330, 820-825 (1994).","DOI":"10.1056\/NEJM199403243301204"},{"key":"10.1016\/j.intimp.2023.109882_b0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0140","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0145","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1634\/theoncologist.2012-0123","article-title":"Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma","volume":"17","author":"Herndon","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2023.109882_b0150","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.109882_b0155","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.109882_b0160","doi-asserted-by":"crossref","first-page":"JCO1800632","DOI":"10.1200\/JCO.18.00632","article-title":"Phase Ib\/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma","volume":"36","author":"Davar","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0165","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109882_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114112","article-title":"Engineering interferons and interleukins for cancer immunotherapy","volume":"182","author":"Holder","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2023.109882_b0175","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/0002-9378(95)90404-2","article-title":"Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived)","volume":"172","author":"Friedman-Kien","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.intimp.2023.109882_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/v14061128","article-title":"Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis","volume":"14","author":"Huang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2023.109882_b0185","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2023.109882_b0190","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109882_b0195","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/302305a0","article-title":"Structure and expression of a cloned cDNA for human interleukin-2","volume":"302","author":"Taniguchi","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109882_b0200","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.6367046","article-title":"Biological activity of recombinant human interleukin-2 produced in Escherichia coli","volume":"223","author":"Rosenberg","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109882_b0205","first-page":"235","article-title":"Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells","volume":"49","author":"Thompson","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering IL-2 to Give New Life to T Cell Immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0215","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0220","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/1744666X.2014.875856","article-title":"Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy","volume":"10","author":"Skrombolas","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-2-17","article-title":"Forecasting the cytokine storm following systemic interleukin (IL)-2 administration","volume":"2","author":"Panelli","year":"2004","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0230","first-page":"123","article-title":"Next-generation cytokines for cancer immunotherapy","volume":"4","author":"Xue","year":"2021","journal-title":"Antib Ther"},{"key":"10.1016\/j.intimp.2023.109882_b0235","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/S0021-9258(18)71855-3","article-title":"Purification and properties of colony-stimulating factor from mouse lung-conditioned medium","volume":"252","author":"Burgess","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2023.109882_b0240","doi-asserted-by":"crossref","unstructured":"J.D. Griffin, et al. The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning 8 Suppl 1, 35-44; discussion 44-35 (1990).","DOI":"10.1002\/stem.5530080705"},{"key":"10.1016\/j.intimp.2023.109882_b0245","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood.V56.6.947.947","article-title":"The nature and action of granulocyte-macrophage colony stimulating factors","volume":"56","author":"Burgess","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2023.109882_b0250","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1126\/science.2990035","article-title":"The granulocyte-macrophage colony-stimulating factors","volume":"229","author":"Metcalf","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109882_b0255","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.82.18.6250","article-title":"Cloning, sequence, and expression of a human granulocyte\/macrophage colony-stimulating factor","volume":"82","author":"Cantrell","year":"1985","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.109882_b0260","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1600-0609.1995.tb00713.x","volume":"55","author":"Hussein","year":"1995","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.intimp.2023.109882_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.706186","article-title":"Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?","volume":"12","author":"Lazarus","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0270","doi-asserted-by":"crossref","unstructured":"R, O.D. An update on GM-CSF and its potential role in melanoma management. Melanoma Manag 7, MMT49 (2020).","DOI":"10.2217\/mmt-2020-0011"},{"key":"10.1016\/j.intimp.2023.109882_b0275","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b0280","first-page":"1738","article-title":"Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor","volume":"5","author":"Small","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b0285","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0290","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40265-021-01467-4","article-title":"Naxitamab: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2023.109882_b0295","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0300","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2011.37.6236","article-title":"Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor","volume":"30","author":"Cheung","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0305","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/ijc.28851","article-title":"Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma","volume":"135","author":"Cheung","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2023.109882_b0310","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0165-6147(86)90352-4","article-title":"Biological response modifiers: realizing their potential in cancer therapeutics","volume":"7","author":"Talmadge","year":"1986","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2023.109882_b0315","first-page":"31","article-title":"Phase I trials of biological response modifiers","volume":"12","author":"Smalley","year":"1986","journal-title":"Drugs Exp. Clin. Res."},{"key":"10.1016\/j.intimp.2023.109882_b0320","first-page":"454","article-title":"Biological response modifiers: preclinical and clinical results","volume":"9","author":"Talmadge","year":"1987","journal-title":"Cancer Chemother. Biol. Response Modif."},{"key":"10.1016\/j.intimp.2023.109882_b0325","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00199531","article-title":"Treatment of carcinoma in situ of the bladder with BCG","volume":"9","author":"Morales","year":"1980","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2023.109882_b0330","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-5347(17)42445-1","article-title":"Role of fibronectin in intravesical BCG therapy for superficial bladder cancer","volume":"139","author":"Ratliff","year":"1988","journal-title":"J. Urol."},{"key":"10.1016\/j.intimp.2023.109882_b0335","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1172\/JCI116202","article-title":"Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells","volume":"91","author":"Kuroda","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2023.109882_b0340","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","article-title":"Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy","volume":"99","author":"Jackson","year":"1995","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0345","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000087163","article-title":"Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guerin for superficial bladder tumors","volume":"75","author":"Eto","year":"2005","journal-title":"Urol. Int."},{"key":"10.1016\/j.intimp.2023.109882_b0350","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/181987","article-title":"Bladder Cancer Immunotherapy: BCG and Beyond","volume":"2012","author":"Askeland","year":"2012","journal-title":"Adv Urol"},{"key":"10.1016\/j.intimp.2023.109882_b0355","doi-asserted-by":"crossref","first-page":"137ra172","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0360","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2249.2006.03191.x","article-title":"Role of Th1-stimulating cytokines in bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells","volume":"146","author":"Luo","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0365","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2023.109882_b0370","doi-asserted-by":"crossref","unstructured":"M. Naoe, et al. Bacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. Int. J. Urol. 14 (2007) 532-538; discussion 538.","DOI":"10.1111\/j.1442-2042.2006.01697.x"},{"key":"10.1016\/j.intimp.2023.109882_b0375","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.intimp.2023.109882_b0380","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000492722","article-title":"Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients","volume":"101","author":"Krajewski","year":"2018","journal-title":"Urol. Int."},{"key":"10.1016\/j.intimp.2023.109882_b0385","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)67523-4","article-title":"Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin","volume":"163","author":"Brake","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.intimp.2023.109882_b0390","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1464-410X.2003.04764.x","article-title":"Bacillus Calmette-Guerin therapy in stage Ta\/T1 bladder cancer: prognostic factors for time to recurrence and progression","volume":"93","author":"Andius","year":"2004","journal-title":"BJU Int."},{"key":"10.1016\/j.intimp.2023.109882_b0395","doi-asserted-by":"crossref","unstructured":"O. Shahin, G.N. Thalmann, C. Rentsch, L. Mazzucchelli, U.E. Studer, A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J. Urol. 169 (2003) 96-100; discussion 100.","DOI":"10.1016\/S0022-5347(05)64044-X"},{"key":"10.1016\/j.intimp.2023.109882_b0400","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0090-4295(98)00369-0","article-title":"Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder","volume":"52","author":"Baniel","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.intimp.2023.109882_b0405","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Guerin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"Larsen","year":"2020","journal-title":"APMIS"},{"key":"10.1016\/j.intimp.2023.109882_b0410","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030694","article-title":"From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guerin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)","volume":"14","author":"Deininger","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2023.109882_b0415","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0420","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4161\/onci.20931","article-title":"Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2023.109882_b0425","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0008-8749(76)90053-8","article-title":"Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components","volume":"21","author":"Audibert","year":"1976","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0430","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/eji.1830080804","article-title":"The macrophage, target cell of the synthetic adjuvant muramyl dipeptide","volume":"8","author":"Fevrier","year":"1978","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0435","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.4049\/jimmunol.119.6.2073","article-title":"Potentiation of the immune response to influenza virus subunit vaccines","volume":"119","author":"Webster","year":"1977","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0440","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jlb.36.2.111","article-title":"Changes in rabbit febrile responses to muramyl dipeptide (MDP) after coupling to a synthetic carrier","volume":"36","author":"Riveau","year":"1984","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2023.109882_b0445","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0192-0561(84)90008-0","article-title":"Pharmacokinetics and metabolism of muramyl dipeptide and nor-muramyl dipeptide [3H-labelled] in the mouse","volume":"6","author":"Ambler","year":"1984","journal-title":"Int. J. Immunopharmacol"},{"key":"10.1016\/j.intimp.2023.109882_b0450","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0192-0561(79)90028-6","article-title":"Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse","volume":"1","author":"Parant","year":"1979","journal-title":"Int. J. Immunopharmacol"},{"key":"10.1016\/j.intimp.2023.109882_b0455","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-18-3997","article-title":"Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors","volume":"25","author":"Bekaii-Saab","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b0460","unstructured":"M.E. Key, J.E. Talmadge, W.E. Fogler, C. Bucana, I.J. Fidler, Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J. Natl. Cancer Inst .69 (1982) 1198-1198."},{"key":"10.1016\/j.intimp.2023.109882_b0465","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.4049\/jimmunol.132.4.2105","article-title":"Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes","volume":"132","author":"Sone","year":"1984","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0470","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnci\/81.12.935","article-title":"Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide","volume":"81","author":"MacEwen","year":"1989","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.intimp.2023.109882_b0475","first-page":"492","article-title":"Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer","volume":"9","author":"Creaven","year":"1990","journal-title":"J. Biol. Response Mod."},{"key":"10.1016\/j.intimp.2023.109882_b0480","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/TCRM.S5688","article-title":"Review of mifamurtide in the treatment of patients with osteosarcoma","volume":"6","author":"Kager","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.intimp.2023.109882_b0485","first-page":"99","article-title":"The adjuvant properties of a nontoxic monophosphoryl lipid A in hyporesponsive and aging mice","volume":"6","author":"Tomai","year":"1987","journal-title":"J. Biol. Response Mod."},{"key":"10.1016\/j.intimp.2023.109882_b0490","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0192-0561(86)90088-3","article-title":"Relationship between immune system and gram-negative bacteria. Acid-treated Salmonella minnesota R595 (Re) enhances immune responsiveness in patients with gynecologic malignancies","volume":"8","author":"Jirillo","year":"1986","journal-title":"Int. J. Immunopharmacol"},{"key":"10.1016\/j.intimp.2023.109882_b0495","doi-asserted-by":"crossref","unstructured":"N. Gar\u00e7on, V.M.M., M. Wettendorff, Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt. In: Schijns VEJC, O.H.D. (ed). Immunopotentiators in Modern Vaccines. Academic Press: London, 2006, pp 161-177.","DOI":"10.1016\/B978-012088403-2\/50011-3"},{"key":"10.1016\/j.intimp.2023.109882_b0500","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/1055-9965.EPI-12-0558","article-title":"Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials","volume":"21","author":"Safaeian","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.intimp.2023.109882_b0505","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0510","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2023.109882_b0515","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.intimp.2023.109882_b0520","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0525","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0530","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-1-4615-1823-5_21","article-title":"Monophosphoryl lipid A as an adjuvant. Past experiences and new directions","volume":"6","author":"Ulrich","year":"1995","journal-title":"Pharm. Biotechnol."},{"key":"10.1016\/j.intimp.2023.109882_b0535","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.4049\/jimmunol.0900164","article-title":"Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity","volume":"183","author":"McKee","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0540","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2023.109882_b0545","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2023.109882_b0550","doi-asserted-by":"crossref","unstructured":"JD., C. Development of the CpG adjuvant 1018: a case study. In: Totowa: (ed). Methods in molecular biology. Humana Press Inc., 2017, pp 15-27.","DOI":"10.1007\/978-1-4939-6445-1_2"},{"key":"10.1016\/j.intimp.2023.109882_b0555","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1086\/517472","article-title":"A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod","volume":"178","author":"Tyring","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2023.109882_b0560","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1128\/AAC.32.5.678","article-title":"Efficacy of S26308 against guinea pig cytomegalovirus infection","volume":"32","author":"Chen","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.intimp.2023.109882_b0565","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0166-3542(88)90032-0","article-title":"Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection","volume":"10","author":"Harrison","year":"1988","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2023.109882_b0570","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/jlb.55.2.234","article-title":"Cytokine induction in mice by the immunomodulator imiquimod","volume":"55","author":"Reiter","year":"1994","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2023.109882_b0575","first-page":"3528","article-title":"Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine","volume":"52","author":"Sidky","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b0580","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1067\/mjd.2002.123492","article-title":"Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis","volume":"47","author":"Persaud","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.109882_b0585","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2023.109882_b0590","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies","volume":"50","author":"Geisse","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.109882_b0595","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0190-9622(99)70261-6","article-title":"Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream","volume":"41","author":"Beutner","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.109882_b0600","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0002-9343(97)00181-2","article-title":"Therapeutic approaches to genital warts","volume":"102","author":"Beutner","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0605","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/jinf.2000.0709","article-title":"Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study","volume":"41","author":"Syed","year":"2000","journal-title":"J. Infect."},{"key":"10.1016\/j.intimp.2023.109882_b0610","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0615","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/sj.jid.5700286","article-title":"The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion","volume":"126","author":"Schon","year":"2006","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.intimp.2023.109882_b0620","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1172\/JCI61034","article-title":"Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells","volume":"122","author":"Drobits","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2023.109882_b0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1415.045","article-title":"History of the discovery of the thymosins","volume":"1112","author":"Goldstein","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2023.109882_b0630","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1073\/pnas.74.2.725","article-title":"Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide","volume":"74","author":"Goldstein","year":"1977","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.109882_b0635","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fonc.2019.00873","article-title":"A Reappraisal of Thymosin Alpha1 in Cancer Therapy","volume":"9","author":"Costantini","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0640","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/0959-8049(95)00477-7","article-title":"Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a","volume":"31a","author":"Garaci","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2023.109882_b0645","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbrc.2015.06.132","article-title":"Thymosin \u03b11 promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1","volume":"464","author":"Yuan","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2023.109882_b0650","first-page":"756","article-title":"Impact of thymosin \u03b11 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis","volume":"134","author":"Guo","year":"2021","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.intimp.2023.109882_b0655","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2022.07.009","article-title":"Efficacy of Thymosin \u03b11 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043)","volume":"114","author":"Liu","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.intimp.2023.109882_b0660","article-title":"Cancer Vaccines: Promising Therapeutics or an Unattainable Dream","volume":"9","author":"Donninger","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2023.109882_b0665","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/14760584.3.4.349","article-title":"Vaccines for neonatal viral infections: hepatitis B vaccine","volume":"3","author":"Cutts","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2023.109882_b0670","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B Vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J. Infect. Dis"},{"key":"10.1016\/j.intimp.2023.109882_b0675","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bpobgyn.2020.02.009","article-title":"HPV vaccination and cancer prevention","volume":"65","author":"Athanasiou","year":"2020","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.intimp.2023.109882_b0680","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: Opportunity and challenge","volume":"471","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2023.109882_b0685","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virol.2011.09.018","article-title":"Dominant role of HPV16 E7 in anal carcinogenesis","volume":"421","author":"Thomas","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.intimp.2023.109882_b0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102439","article-title":"Current state of play for HPV-positive oropharyngeal cancers","volume":"110","author":"Deutsch","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2023.109882_b0695","doi-asserted-by":"crossref","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","article-title":"Biological and clinical aspects of HPV-related cancers","volume":"17","author":"Szymonowicz","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0700","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","article-title":"Penile cancer","volume":"7","author":"Thomas","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2023.109882_b0705","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2023.109882_b0710","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.intimp.2023.109882_b0715","doi-asserted-by":"crossref","unstructured":"M. Drolet, E. Benard, N. Perez, M. Brisson, H.P.V.V.I.S. Group, Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 394, 497-509 (2019).","DOI":"10.1016\/S0140-6736(19)30298-3"},{"key":"10.1016\/j.intimp.2023.109882_b0720","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/jnci\/djab080","article-title":"Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer","volume":"113","author":"Kjaer","year":"2021","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.intimp.2023.109882_b0725","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2023.109882_b0730","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109882_b0735","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamaoto.2021.3567","article-title":"Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001\u20132017","volume":"148","author":"Damgacioglu","year":"2022","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.intimp.2023.109882_b0740","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoto.2021.3786","article-title":"Population Trends and Long-term Outlook for Oropharyngeal Cancer: Have We Found a Silver Lining?","volume":"148","author":"Osazuwa-Peters","year":"2022","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.intimp.2023.109882_b0745","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2017.75.0141","article-title":"Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States","volume":"36","author":"Chaturvedi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0750","doi-asserted-by":"crossref","first-page":"e68329","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.109882_b0755","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines - A review of the first decade","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0760","doi-asserted-by":"crossref","first-page":"415","DOI":"10.15585\/mmwr.mm7012a2","article-title":"Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003\u20132018","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.intimp.2023.109882_b0765","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.clpt.6100055","article-title":"GARDASIL: prophylactic human papillomavirus vaccine development\u2013from bench top to bed-side","volume":"81","author":"Shi","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2023.109882_b0770","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18\u201345 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.intimp.2023.109882_b0775","doi-asserted-by":"crossref","first-page":"212 e211","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","volume":"215","author":"Hildesheim","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.intimp.2023.109882_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2019.100170","article-title":"Towards the global elimination of cervical cancer","volume":"8","author":"Canfell","year":"2019","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.intimp.2023.109882_b0785","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109882_b0790","article-title":"The Efficacy of Therapeutic DNA Vaccines Expressing the Human Papillomavirus E6 and E7 Oncoproteins for Treatment of Cervical Cancer: Systematic Review","volume":"10","author":"Akhatova","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2023.109882_b0795","doi-asserted-by":"crossref","DOI":"10.3390\/v14020239","article-title":"Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials","volume":"14","author":"Tang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2023.109882_b0800","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2020.02.031","article-title":"A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6\/E7 Oncogenes After Chemoradiation for Cervical Cancer","volume":"107","author":"Hasan","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.intimp.2023.109882_b0805","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI114525","article-title":"Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro","volume":"85","author":"Markowicz","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2023.109882_b0810","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/imt.10.77","article-title":"Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer","volume":"3","author":"Madan","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2023.109882_b0815","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0820","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.intimp.2023.109882_b0825","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061454","article-title":"Radiolabeled Antibodies for Cancer Imaging and Therapy","volume":"14","author":"Parakh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2023.109882_b0830","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2023.109882_b0835","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002931","article-title":"Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T","volume":"9","author":"Dorff","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2023.109882_b0840","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b0845","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0850","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1245\/s10434-018-6658-4","article-title":"An Update on Immunotherapy for Solid Tumors: A Review","volume":"25","author":"Pham","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0855","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines4030018","article-title":"From Benchtop to Bedside: A Review of Oncolytic Virotherapy","volume":"4","author":"Choi","year":"2016","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2023.109882_b0860","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2023.109882_b0865","doi-asserted-by":"crossref","unstructured":"J. Galon, D. Bruni, Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18 (2019) 197-218.","DOI":"10.1038\/s41573-018-0007-y"},{"key":"10.1016\/j.intimp.2023.109882_b0870","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.109882_b0875","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.4049\/jimmunol.136.9.3282","article-title":"A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes","volume":"136","author":"Martin","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0880","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1432-1033.1984.tb08263.x","article-title":"A 45-kDa human T-cell membrane glycoprotein functions in the regulation of cell proliferative responses","volume":"142","author":"Gmunder","year":"1984","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.intimp.2023.109882_b0885","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.4049\/jimmunol.154.11.5757","article-title":"Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response","volume":"154","author":"Lucas","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0890","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0895","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nri3740","article-title":"T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?","volume":"14","author":"Speiser","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0900","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0905","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0910","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2023.109882_b0915","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109882_b0920","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0925","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0930","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fimmu.2019.00617","article-title":"BTLA\/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection","volume":"10","author":"Yu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b0935","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0940","first-page":"5935","article-title":"Monoclonal Antibodies for the Treatment of Cancer","volume":"37","author":"Pento","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.intimp.2023.109882_b0945","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","article-title":"Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer","volume":"65","author":"Graziani","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2023.109882_b0950","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b0955","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd3463","article-title":"Ipilimumab","volume":"10","author":"Sondak","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2023.109882_b0960","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0965","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1093\/annonc\/mdt161","article-title":"Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials","volume":"24","author":"Wolchok","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0970","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0975","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b0980","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103040","article-title":"Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials","volume":"62","author":"Mankor","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2023.109882_b0990","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b0995","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1000","doi-asserted-by":"crossref","unstructured":"Kathryn Cole, Q.L., Michael Hollingsworth, Jesse Cox, James Padussis, Jason Foster, Luciano Vargas, James E. Talmadge. Human Splenic Myeloid Derived Suppressor Cells: Phenotypic and Clustering Analysis Cellular Immunology (2021).","DOI":"10.1016\/j.cellimm.2021.104317"},{"key":"10.1016\/j.intimp.2023.109882_b1005","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.3747\/co.25.3976","article-title":"Targeting the PD-1\/PD-L1 axis for the treatment of non-small-cell lung cancer","volume":"25","author":"Meyers","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/cgt.2016.19","article-title":"Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases","volume":"23","author":"Thorn","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.intimp.2023.109882_b1015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1020","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1025","doi-asserted-by":"crossref","unstructured":"P. Darvin, S.M. Toor, V. Sasidharan Nair, E. Elkord, Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50 (2018) 1-11.","DOI":"10.1038\/s12276-018-0191-1"},{"key":"10.1016\/j.intimp.2023.109882_b1030","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109882_b1040","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109882_b1045","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109882_b1050","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2023.109882_b1055","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41585-021-00499-5","article-title":"Pembrolizumab use in bladder cancer: a tale of two trials","volume":"18","author":"Aragon-Ching","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.intimp.2023.109882_b1060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ejh.12770","article-title":"Pembrolizumab in classical Hodgkin's lymphoma","volume":"97","author":"Maly","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.intimp.2023.109882_b1065","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2020.1792881","article-title":"Pembrolizumab for the treatment of esophageal cancer","volume":"20","author":"Yamamoto","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2023.109882_b1070","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14204985","article-title":"Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers","volume":"14","author":"Ettl","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2023.109882_b1080","doi-asserted-by":"crossref","first-page":"e1508","DOI":"10.1002\/onco.13810","article-title":"Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"26","author":"Babiker","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2023.109882_b1085","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/annonc\/mdy411","article-title":"Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial","volume":"29","author":"Colevas","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001378","article-title":"Safety and efficacy of single cycle induction treatment with cisplatin\/docetaxel\/ durvalumab\/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8","volume":"8","author":"Hecht","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2023.109882_b1095","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002998","article-title":"Avelumab for platinum-ineligible\/refractory recurrent and\/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial","volume":"9","author":"Guigay","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2023.109882_b1105","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1110","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1120","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109882_b1130","doi-asserted-by":"crossref","first-page":"e0130142","DOI":"10.1371\/journal.pone.0130142","article-title":"Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers","volume":"10","author":"Carbognin","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.109882_b1135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1140","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PAS.0000000000000783","article-title":"PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors","volume":"41","author":"Sloan","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.intimp.2023.109882_b1145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109882_b1150","doi-asserted-by":"crossref","DOI":"10.3390\/cells11152351","article-title":"Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor","volume":"11","author":"Chocarro","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2023.109882_b1155","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1160","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)","volume":"174","author":"Workman","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b1165","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1084\/jem.176.2.327","article-title":"Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens","volume":"176","author":"Baixeras","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1096\/fasebj.10.7.8635694","article-title":"Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production","volume":"10","author":"Annunziato","year":"1996","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2023.109882_b1175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1180","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109882_b1185","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b1190","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ymthe.2022.02.002","article-title":"The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease","volume":"30","author":"Hont","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2023.109882_b1195","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.109882_b1200","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-73259-4_14","article-title":"The T-body approach: redirecting T cells with antibody specificity","volume":"329\u2013342","author":"Eshhar","year":"2008","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.intimp.2023.109882_b1205","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.109882_b1210","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T Cell-Associated Neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b1220","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1225","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","article-title":"Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation","volume":"304","author":"Weiden","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1230","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1235","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1083-8791(99)70011-X","article-title":"Pathophysiologic mechanisms of acute graft-vs.-host disease","volume":"5","author":"Ferrara","year":"1999","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.intimp.2023.109882_b1240","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJM199401133300204","article-title":"Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia","volume":"330","author":"Porter","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1245","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2023.109882_b1250","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41409-020-0798-4","volume":"55","author":"Kothari","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2023.109882_b1255","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bjh.15970","article-title":"Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis","volume":"186","author":"Roy","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2023.109882_b1260","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2005-08-3373","article-title":"A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3\/CD28 costimulation","volume":"107","author":"Porter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2023.109882_b1265","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","article-title":"Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial","volume":"9","author":"Admiraal","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.intimp.2023.109882_b1270","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/s41409-022-01772-w","article-title":"Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL","volume":"57","author":"Al-Kadhimi","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2023.109882_b1275","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1280","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1285","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1290","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1182\/blood-2003-01-0095","article-title":"Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed\/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation","volume":"102","author":"Laport","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2023.109882_b1295","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-09-0418","article-title":"Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells","volume":"15","author":"Rapoport","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b1300","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/nm1310","article-title":"Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer","volume":"11","author":"Rapoport","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2010-07-296822","article-title":"Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial","volume":"117","author":"Stadtmauer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2023.109882_b1310","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood-2010-08-299396","article-title":"Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma","volume":"117","author":"Rapoport","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2023.109882_b1315","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-13-2817","article-title":"Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3\/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells","volume":"20","author":"Rapoport","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b1320","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1325","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PPO.0b013e31824d4465","article-title":"Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook","volume":"18","author":"Wu","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.intimp.2023.109882_b1330","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/0008-5472.CAN-06-3388","article-title":"High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer","volume":"67","author":"Piersma","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2023.109882_b1335","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.2015.63.0970","article-title":"Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer","volume":"34","author":"Brambilla","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1340","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b1345","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/hep.28344","article-title":"Liver inflammation and cancer: The role of tissue microenvironment in generating the tumor-promoting niche (TPN) in the development of hepatocellular carcinoma","volume":"63","author":"Galun","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2023.109882_b1350","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2023.109882_b1355","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1360","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2023.109882_b1365","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcyt.2018.11.004","article-title":"Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process","volume":"21","author":"Hopewell","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.intimp.2023.109882_b1370","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CJI.0b013e3181f05b91","article-title":"Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL","volume":"33","author":"Goff","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2023.109882_b1375","doi-asserted-by":"crossref","unstructured":"J.B.A.G. Haanen, M.R., T.H. Borch, J.H. van den Berg. LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial. Ann. Oncolo. 33 (2022).","DOI":"10.1016\/j.annonc.2022.08.036"},{"key":"10.1016\/j.intimp.2023.109882_b1380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174160","article-title":"Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2023.109882_b1385","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4049\/jimmunol.163.1.507","article-title":"Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity","volume":"163","author":"Clay","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109882_b1390","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109882_b1395","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41591-022-01786-3","article-title":"Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA","volume":"28","author":"Chandran","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1400","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109882_b1405","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1410","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2023.109882_b1415","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1420","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/jha2.338","article-title":"Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice","volume":"3","author":"Sengsayadeth","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.intimp.2023.109882_b1425","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1430","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1435","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1440","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.109882_b1445","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1450","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109882_b1455","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1460","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109882_b1465","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109882_b1470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:59:15Z","timestamp":1761587955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923002023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":294,"alternative-id":["S1567576923002023"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109882","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highlights into historical and current immune interventions for cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109882"}}